Varenicline increased the odds of successful long-term smoking cessation approximately threefold compared with pharmacologically unassisted quit attempts.Source. Wikipedia article.
In trials reported so far, more participants quit successfully with varenicline than with bupropion. The effectiveness of varenicline as an aid to relapse prevention has not been clearly established. The main adverse effect of varenciline is nausea, but this is mostly at mild to moderate levels and tends to reduce with habituation.
There is a need for independent trials of varenicline versus placebo, to test the early findings. There is also a need for direct comparisons with nicotine replacement therapy, and for further trials with bupropion, to establish the relative efficacy of the treatments.
Saturday, January 27, 2007
New studies boost varenicline for smoking cessation
The smoking cessation drug varenicline, recently introduced in the U.S. under the brand name Chantix (Pfizer), has fared well in early studies reviewed by the Cochrane Library this month. Cochrane's authors write: